604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status.
Saved in:
| Title: | 604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status. |
|---|---|
| Authors: | Brose, M.S.1 (AUTHOR), Keam, B.2 (AUTHOR), Robinson, B.3 (AUTHOR), Sherman, S.4 (AUTHOR), Krajewska, J.A.5 (AUTHOR), Lin, C-C.6 (AUTHOR), Vaisman, F.7 (AUTHOR), Hoff, A.O.8 (AUTHOR), Hitre, E.9 (AUTHOR), Bowles, D.W.10 (AUTHOR), Ngamphaiboon, N.11 (AUTHOR), Guo, X.12 (AUTHOR), Zhang, F.12 (AUTHOR), Schwickart, M.12 (AUTHOR), Williamson, D.S.13 (AUTHOR), Curran, D.14 (AUTHOR), Berry, N.15 (AUTHOR), Capdevila Castillon, J.16 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1708-S1709. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.10.319 |
